safety of tumor necrosis factor blockers in adult’s and children’s rheumatologic practice

Clicks: 179
ID: 158107
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #22 of 111 articles by views in Biocontrol science

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract

The article presents the review of a safety of TNF blockers in treatment of rheumatologic diseases in adults and children. Authors give a data on separate, open-labeled, and multicenter double-blinded placebo-controlled studies of tolerance to infliximab, etanercept and adalimumab. The results of studies show high effectiveness and good safety of TNF blockers in adult’s and children’s rheumatologic practice. 

Key words: children, rheumatoid arthritis, juvenile arthritis, TNF blockers, treatment, safety, infliximab, adalimumab, etanercept.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):82-94)

Reference Key
bzarova2010voprosysafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;T.M. Bzarova;E.I. Alexeeva;S.I. Valieva;A.M. Alekseeva;R.V. Denisova;K.B. Isaeva
Journal Biocontrol science
Year 2010
DOI
DOI not found
URL
http://vsp.spr-journal.ru:80/jour/article/view/832
Keywords
Pediatrics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.